PROTEOMIC STUDY OF BREAST CANCER CELL LINE AFTER HEMIN TREATMENT

SCHWEITZER, K.; COLÓ, G.P.; FERNÁNDEZ CHÁVEZ, L.; ALONSO, E.G.; FÄSSLER, R.; CURINO, A.C.; FACCHINETTI, M.M.

Congreso; Reunión Anual de Sociedades de Biociencia; 2021

Sociedad Argentina de Investigaciones Clínicas

Hemin is a ferriporphyrin (C34H32ClFeN4O4) with antitumoral effects on prostate, breast and colon cancer. It is widely used to increase the expression and activity of hemoxigenase-1 (HO-1). HO-1 is a microsomal enzyme that catalyses the degradation of heme group and can be translocated to subcellular compartments. Our laboratory, among others, has demonstrated that HO-1 regulates several processes related to cancer progression. The aim of this work was to study the protein expression modification due to hemin treatment in a murine breast cancer cell line (LM3). After hemin or vehicle (control) cell treatment, we performed Mass Spectrometry (MS) and Perseus proteome analyses. The proteome analysis showed that 1033 from 7292 proteins detected were modulated after hemin treatment. We observed that 595 proteins were significantly increased, including HO-1, and 353 proteins were significantly decreased in the group treated with hemin respect to their controls (p